Friedman Daniel, Sirven Joseph I
Comprehensive Epilepsy Center, Department of Neurology, NYU Langone School of Medicine, New York, NY, United States.
Department of Neurology, Mayo Clinic Arizona, Phoenix, AZ, United States.
Epilepsy Behav. 2017 May;70(Pt B):298-301. doi: 10.1016/j.yebeh.2016.11.033. Epub 2017 Jan 12.
There has been a dramatic surge in the interest of utilizing cannabis for epilepsy treatment in the US. Yet, access to cannabis for research and therapy is mired in conflicting regulatory policies and shifting public opinion. Understanding the current state of affairs in the medical cannabis debate requires an examination of the history of medical cannabis use. From ancient Chinese pharmacopeias to the current Phase III trials of pharmaceutical grade cannabidiol, this review covers the time span of cannabis use for epilepsy therapy so as to better assess the issues surrounding the modern medical opinion of cannabis use. This article is part of a Special Issue titled Cannabinoids and Epilepsy.
在美国,将大麻用于癫痫治疗的兴趣急剧飙升。然而,用于研究和治疗的大麻获取陷入了相互冲突的监管政策和不断变化的公众舆论之中。要了解医用大麻辩论的当前状况,需要审视医用大麻的使用历史。从中国古代药典到目前的药用级大麻二酚三期试验,这篇综述涵盖了大麻用于癫痫治疗的时间跨度,以便更好地评估围绕现代医用大麻观点的相关问题。本文是名为“大麻素与癫痫”的特刊的一部分。